United States Carrier Screening Market Outlook to 2030: Size, Share, Growth and Trends

The United States Carrier Screening Market is valued at USD 780 Mn in 2024 on an industry-revenue basis at the laboratory or service-provider level. That scope captures test-ordering revenue net of reagent and instrument pass-through, and it includes demand across reference laboratories, hospitals and clinics, physician offices, IVF centers, and research institutions. The size is underpinned by 5.8 Mn tests in 2024 , which confirms that carrier screening has moved beyond a narrow specialty niche and now functions as a scaled reproductive diagnostics category with meaningful recurring demand.

The market is projected to reach USD 1,557 Mn by 2030 , implying a forecast CAGR of 12.2% . That is materially faster than the 9.0% historical CAGR during 2019-2024 , indicating that the next growth phase will be driven by mix expansion rather than simple recovery. The forecast assumes increasing use of expanded carrier screening, broader preconception uptake, more IVF-linked ordering, and gradual improvement in net realized revenue per test as higher-value panels account for a larger share of orders.

Profit pools are shifting toward expanded and digitally enabled workflows. Expanded Carrier Screening already represents USD 312 Mn, or 40.0% of total market value in 2024 , making it the largest segment. At the same time, Direct-to-Consumer and Telehealth-Enabled Carrier Screening is the fastest-growing segment at 22.5% CAGR , even though it remains small in current absolute value. This means future profits are likely to concentrate in operators that can combine broad panel content, digital acquisition, counseling support, and channel integration rather than relying on narrow targeted menus alone.

The main risk is not clinical relevance, but economic execution under a changing reimbursement and compliance environment. The market benefits from near-term pricing stability, yet CLFS policy can still permit up to 15% annual payment reductions during 2027-2029 on affected tests. At the same time, carrier screening often requires counseling, partner follow-up, and payer documentation, which can slow collections and raise fulfillment costs. That combination means growth can remain strong while margins diverge significantly between scaled laboratories and smaller specialist entrants.

The United States is the largest market in the selected peer set and remains the most scalable operating environment for carrier screening. Its size advantage is supported by the largest reproductive cohort, the broadest commercial lab infrastructure, and the deepest fertility-clinic base. Within this report’s peer comparison, the United States ranks first at USD 780 Mn in 2024 and also leads on forecast growth at 12.2% CAGR . That combination of current scale and forward velocity is unusual among developed-market peers, where many markets are smaller and more policy-constrained.

The most important long-term demand driver is the mainstreaming of broader carrier screening inside routine reproductive care, rather than any single condition or patient subgroup. The market sits against a large addressable population anchored by 3,622,673 U.S. births in 2024 , while fertility pathways add specialized demand through 435,426 ART cycles in 2022 . When those two demand pools are combined with society guidance that supports broad offering during pregnancy or preconception, the market gains a structurally recurring order base with multiple monetization points per patient episode.

Expanded Carrier Screening is currently the most defensible segment because it combines broad clinical utility, better revenue density, and strong fit with established laboratory infrastructure. In contrast, Direct-to-Consumer and Telehealth-Enabled Carrier Screening is the most exposed to disruption because it is growing quickly but depends on acquisition efficiency, digital trust, and compliant counseling pathways. Incumbents are advantaged where payer contracts and operational scale matter, while challengers can still gain ground where patient acquisition, cash-pay simplicity, and telehealth-supported conversion create lower-friction demand capture.